Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study

Antonio Tursi, Giammarco Mocci, Linda Cingolani, Edoardo Savarino, Roberta Pica, Andrea Cocco, Maddalena Zippi, Daniele Napolitano, Elisa Schiavoni, Daniela Pugliese, Franco Scaldaferri, Francesco Costa, Manuela Marzo, Mariaelena Serio, Antonella Scarcelli, Laura Bolognini, Emanuele Bendia, Giovanni Maconi, Rosanna Cannatelli, Simona Piergallini, Giorgia Bodini, Francesco Calabrese, Antonio Ferronato, Giuseppe Pranzo, Walter Elisei, Rita Monterubbianesi, Roberto Faggiani, Stefano Rodinò, Ladislava Sebkova, Laurino Grossi, Federica Gaiani, Gianluigi dè Angelis, Roberto Lorenzetti, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Nicola Della Valle, Rodolfo Sacco, Giacomo Forti, Raffaele Colucci, Paolo Tonti, Viviana Neve, Giulia Rocco, Carlotta Sacchi, Costantino Zampaletta, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Francesca Maria Onidi, Paolo Usai Satta, Marcello Picchio, Alfredo Papa

Open source

DOI: 10.1080/14656566.2023.2230126
Published: 2023-06-28
Container: Expert Opinion on Pharmacotherapy
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14656566.2023.2230126,
  title = {Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study},
  author = {Antonio Tursi and Giammarco Mocci and Linda Cingolani and Edoardo Savarino and Roberta Pica and Andrea Cocco and Maddalena Zippi and Daniele Napolitano and Elisa Schiavoni and Daniela Pugliese and Franco Scaldaferri and Francesco Costa and Manuela Marzo and Mariaelena Serio and Antonella Scarcelli and Laura Bolognini and Emanuele Bendia and Giovanni Maconi and Rosanna Cannatelli and Simona Piergallini and Giorgia Bodini and Francesco Calabrese and Antonio Ferronato and Giuseppe Pranzo and Walter Elisei and Rita Monterubbianesi and Roberto Faggiani and Stefano Rodinò and Ladislava Sebkova and Laurino Grossi and Federica Gaiani and Gianluigi dè Angelis and Roberto Lorenzetti and Leonardo Allegretta and Alessia Immacolata Cazzato and Stefano Scorza and Nicola Della Valle and Rodolfo Sacco and Giacomo Forti and Raffaele Colucci and Paolo Tonti and Viviana Neve and Giulia Rocco and Carlotta Sacchi and Costantino Zampaletta and Cristiano Pagnini and Maria Giovanna Graziani and Maria Carla Di Paolo and Francesca Maria Onidi and Paolo Usai Satta and Marcello Picchio and Alfredo Papa},
  year = {2023},
  journal = {Expert Opinion on Pharmacotherapy},
  doi = {10.1080/14656566.2023.2230126},
  url = {https://doi.org/10.1080/14656566.2023.2230126}
}

RIS

TY  - JOUR
TI  - Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
AU  - Antonio Tursi
AU  - Giammarco Mocci
AU  - Linda Cingolani
AU  - Edoardo Savarino
AU  - Roberta Pica
AU  - Andrea Cocco
AU  - Maddalena Zippi
AU  - Daniele Napolitano
AU  - Elisa Schiavoni
AU  - Daniela Pugliese
AU  - Franco Scaldaferri
AU  - Francesco Costa
AU  - Manuela Marzo
AU  - Mariaelena Serio
AU  - Antonella Scarcelli
AU  - Laura Bolognini
AU  - Emanuele Bendia
AU  - Giovanni Maconi
AU  - Rosanna Cannatelli
AU  - Simona Piergallini
AU  - Giorgia Bodini
AU  - Francesco Calabrese
AU  - Antonio Ferronato
AU  - Giuseppe Pranzo
AU  - Walter Elisei
AU  - Rita Monterubbianesi
AU  - Roberto Faggiani
AU  - Stefano Rodinò
AU  - Ladislava Sebkova
AU  - Laurino Grossi
AU  - Federica Gaiani
AU  - Gianluigi dè Angelis
AU  - Roberto Lorenzetti
AU  - Leonardo Allegretta
AU  - Alessia Immacolata Cazzato
AU  - Stefano Scorza
AU  - Nicola Della Valle
AU  - Rodolfo Sacco
AU  - Giacomo Forti
AU  - Raffaele Colucci
AU  - Paolo Tonti
AU  - Viviana Neve
AU  - Giulia Rocco
AU  - Carlotta Sacchi
AU  - Costantino Zampaletta
AU  - Cristiano Pagnini
AU  - Maria Giovanna Graziani
AU  - Maria Carla Di Paolo
AU  - Francesca Maria Onidi
AU  - Paolo Usai Satta
AU  - Marcello Picchio
AU  - Alfredo Papa
PY  - 2023
JO  - Expert Opinion on Pharmacotherapy
DO  - 10.1080/14656566.2023.2230126
UR  - https://doi.org/10.1080/14656566.2023.2230126
ER  -

APA

Tursi, A., Mocci, G., Cingolani, L., Savarino, E., Pica, R., Cocco, A., Zippi, M., Napolitano, D., Schiavoni, E., Pugliese, D., Scaldaferri, F., Costa, F., Marzo, M., Serio, M., Scarcelli, A., Bolognini, L., Bendia, E., Maconi, G., Cannatelli, R., Piergallini, S., Bodini, G., Calabrese, F., Ferronato, A., Pranzo, G., Elisei, W., Monterubbianesi, R., Faggiani, R., Rodinò, S., Sebkova, L., Grossi, L., Gaiani, F., Angelis, G. D., Lorenzetti, R., Allegretta, L., Cazzato, A. I., Scorza, S., Valle, N. D., Sacco, R., Forti, G., Colucci, R., Tonti, P., Neve, V., Rocco, G., Sacchi, C., Zampaletta, C., Pagnini, C., Graziani, M. G., Paolo, M. C. D., Onidi, F. M., Satta, P. U., Picchio, M., & Papa, A. (2023). Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2023.2230126

Source records

crossref · retrieved 2026-09-26T20:23:57.004Z